Moderna Wins Bivalent COVID-19 Vaccine Booster Race With First Approval
Conditional UK Nod Puts Moderna In Lead
Moderna takes the next step in the in the development of COVID-19 vaccines, with the first approval of the first bivalent vaccine that can produce a broader immune response to new SARS-CoV-2 variants.
You may also be interested in...
The French firm has suspended the manufacturing of its COVID-19 vaccine, instead emphasizing its hopes in advanced Lyme disease and Chikungunya.
New supply arrangements with the two firms are expected to offer greater protection to people in Europe as the autumn/winter season approaches. The EU’s health crisis preparedness body HERA has also identified its “top three health threats.”
A protein-based vaccine for COVID-19 reaches the US at last, but Novavax looks set miss out once again as the fall deadline for BA.4/5 variant-targeting vaccines approaches.